Chen Z, Song T, Yan Y, et al
The increasing prevalence of obesity and type 2 diabetes in Europe, combined with the growing awareness of advanced treatment options, drives the demand for GLP-1 receptor agonists
BPC-157 Whereas BPC-157 is hardly new to the news for healing properties, it would be a significant help in weight reduction if faster recovery and less inflammation can be afforded
Reconstitution BPC-157 ships as a lyophilized (freeze-dried) powder
Morgan Stanley projects the weight-loss medication market could reach $150B by 2035, up from the $15B figure in 2024
AFRICA Research has found that Tesamorelin increases IGF-1 levels, supporting metabolism and tissue repair while having a shorter half-life than other GHRH analogs